Hebbian Bio’s Post

🚀DEALFLASH - WEEK 42🚀 An overview of early-stage deals in European bio-, health- and life sciences. pre-seed. 🧫Corium Biotech Scope: Corium Biotech ™ is a brand by Maia & Muller – Biotech which manufactures exotic leather using cellular agriculture technologies. Investors: biotope by VIB, Portugal Ventures Ticket size: EUR 500k seed. 👁️Siloton Scope: Siloton is a medical device manufacturing company that designs and develops diagnostic imaging devices in the field of ophthalmology. Investors: Evenlode Foundation, South East Angels, The Francis Crick Institute Ticket size: GBP 860k 📈SOMAREALITY Scope: Spatial Computing, Eye Tracking, Cognitive Digital Biomarkers Investors: n/a Ticket size: EUR 2.6 MM 🔬Antiverse Scope: Antiverse is dedicated to engineering the future of drug development to change the course of people's lives. Investors: AngelHub, Future Planet Capital, i&i Biotech Fund, Innospark Ventures, Kadmos Capital Ltd, Tensor Ventures, UK Innovation & Science Seed Fund Ticket size: GBP 3.5 MM 🧪Aerleum Scope: Aerleum Develops a groundbreaking system that combines CO2 capture and conversion to produce clean fuels and chemicals. Investors: 360 Capital, Bpifrance, HTGF | High-Tech Gründerfonds, Marble, Norrsken VC Ticket size: EUR 5.5 MM ⚙️Shift Bioscience Scope: Simulation guided target discovery for age-linked diseases Investors: BGF, F-Prime Capital, Kindred Capital VC, Meltwind Advisory LLP & angel investors Ticket size: GBP 12.5 MM series a. 🍴UMAMI Scope: Umami is a bionic farming company specialized in growing pure food with superior flavour. Investors: n/a Ticket size: CHF 4.3 MM 👨⚕️Minze Health Scope: Minze Health is a health tech start-up that builds digital health solutions for urology and pelvic health. Investors: Capricorn Partners, imec.istart future fund, PMV, White Fund SA Ticket size: USD 5.3 MM 💊invIOs INNOVATIVE IMMUNO-ONCOLOGY Scope: invIOs is a private biotech company that specializes in the discovery and development of next-generation cancer therapies. Investors: Ligand Pharmaceuticals Ticket size: EUR 8.2 MM other. 📊Kaminari Medical Scope: Kaminari Medical combines ultrasound and optical imaging to revolutionise coronary revascularisation Investors: Demcon, Graduate Entrepreneur Fund, Libertatis Ergo Holding B.V., NLC Health Ventures Ticket size: EUR 2.3 MM Looking for easier and more successful fundraising in bio-, health- and life sciences? Contact us at hello@ensemblate.com. #innovation #lifesciences #fundraising #venturecapital

Emerging Trends In AI In Biotech ☣️ "The intersection of artificial intelligence (AI) and biotechnology is revolutionizing the healthcare landscape, offering opportunities for venture capitalists (VCs) to drive innovation and achieve significant returns on investment. This article delves into the key trends in AI in biotech and provides actionable strategies for VCs to navigate this dynamic sector..." Read more >> https://bit.ly/462G5au #UKSPF #SwanseaUni #NaturalProducts #BioTech #AI #EmergingTrends #VentureCapital #Innovation #Entrepreneurship

At October's ASN Kidney Week, Aiosyn's partner showed the impact that #AI-powered image analysis is having in drug efficacy studies. 💪 Read on below for how Aiosyn helps with this.🔻 At the 📍 San Diego event, Physiogenex presented its groundbreaking advancements in preclinical kidney models using AI-powered image analysis. Aiosyn supports this collaboration with its NephroPath platform, which provides precise assessments of tubuli impairment, glomerulosclerosis and mesangial expansion. Aiosyn’s AI solutions empower pathologists to make their work more accurate, efficient and effective, for the benefit of patients and society. 🔬 Interested in what the picture below shows us? For more information on these results, click here > https://lnkd.in/ejUbZ_MR #innovation #startup #goodthingsarecoming #impactinvesting #medtech

Inside the Seattle Labs of Xaira, the AI-Powered Startup Launched with $1B from Investors https://lnkd.in/gw4ykt92 Xaira Therapeutics – a spinout from the University of Washington’s Institute for Protein Design (IPD) – merges AI with science to create generative models for developing new therapeutics, revolutionizing traditional approaches to treating diseases. Founded by IPD alumni, Xaira is rapidly making strides in the biotech space, as evidenced by their launch in April with over $1 billion in committed funding. Unlike traditional methods that rely on natural templates, Xaira utilizes AI models to design proteins that surpass nature’s designs, including novel antibodies that can bind to human receptors. “There’s very few places that marry tech and biotech in the way that Seattle is set up to do,” said Hetu Kamisetty, head of Xaira’s Seattle location. “For protein design, this is the place to be.” The post Inside the Seattle Labs of Xaira, the AI-Powered Startup Launched with $1B from Investors appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Well well well, here we are again. Last week I posted about our first batch of 20 Start-ups joining us at BioTechX, now were super close to our first 30! Introducing the latest 4 Startups to join BioTechX: ADLIN Science - Created a multi-omics tool which to support labs and researchers with their Omic data analysis. This helps save time, gain scientific efficiency and valorise data. Raidium - Raidium have created an interactive AI platform which allows for access to imaging biomarkers. Allow for clinical research to be quicker which in turns helps healthcare and its patients. Xgenera - Through creating a strong diagnostic test (which works at every cancer stage), Xgenera are able to detect cancer quicker and the quicker its detected, the more treatable it is. Kaleidoscope.bio - Helping R&D teams by providing more clarity to their data which in turn helps deliver's outcomes faster and more efficiently. It also keeps key stakeholders keep up to date with the progress of any given project. If there is one word that connects all these Start-ups, its efficiency. Through making the healthcare industry even slightly more effcient can result in big positive changes and you can only bring about that level of change by working with leaders within the life science industry. Thats where BioTechX comes in, we aim to connect Start-ups with over 3000 C-level executives within the life science industry as well as investors to really showcase what these companies can do and make positive impacts within healthcare. If you are a Startup looking to network with industry leaders to help develop new partnerships in Basel this October 9-10, dont hesitate to get in touch, we still have a few spaces left! #lifescience #biotech #startups #pharma #basel

📈📉 2024: A bitter-sweet but eventful year for biotech, according to a new report via Labiotech.eu. Some quick insights (also with a bit of my input here): 🧬 While startups saw a resurgence in large-scale funding, like examples of Xaira Therapeutics with staggering $1 billion round, mergers and acquisitions (M&A) declined, signaling a shift toward quality investments. 🧬 Building on 2023's approval of Casgevy, 2024 saw advances in gene-editing technologies, clinical trials, and new partnerships focused on CRISPR-based therapies. 🧬 AI continued to be a wildly discussed force in biotech, with major contributions from tech giants like Google and NVIDIA. The "Techbio" space saw closer collaborations between technology and biotech venture capital firms, while a small number of AI-driven companies began to see early signs of success in clinical trials of AI-discovered molecules (e.g. Insilico Medicine, Lantern Pharma Inc. (Nasdaq: LTRN) etc). 🧬 New treatments for Alzheimer’s disease and other neurological conditions advanced, with notable approvals like donanemab (Kisunla) and new focuses on tau-targeting therapies. Notable FDA Approvals: 💊 oncology (e.g., Tecelra, Bizengri, KRAZATI), 💊 neurology (e.g., Vyalev), 💊 rare diseases (e.g., Yorvipath for hypoparathyroidism), 💊 infectious diseases (e.g., Mresvia for RSV). Despite successes, 2024 was marked by layoffs in companies like Ginkgo Bioworks, Inc. and 23andMe, reflecting broader economic challenges and funding volatility. Geopolitical tensions, especially between the U.S. and China, led to the introduction of the BIOSECURE Act, impacting biotech supply chains and reshaping global CDMO partnerships. All in all, while 2024 displayed signs of recovery, challenges like regulatory hurdles, geopolitical risks, and funding volatility remain. Nevertheless, landmark acquisitions (e.g., Exscientia by Recursion) and new approvals were some positive developments. Kudos to Jules ADAM for writing this insightful report. And what do you expect biotech will look like in 2025? Write in the comments! #biotech #drugdiscovery Image credit: Labiotech

Artificial intelligence is revolutionizing drug discovery, exemplified by GSK's recent $300M partnership with Relation Therapeutics to develop treatments for osteoarthritis and fibrotic diseases. This collaboration leverages machine learning to analyze human tissue data, aiming to reduce drug discovery failures. Similarly, Dimension has raised $500M for its second venture fund to support startups integrating AI with life sciences, underscoring the growing convergence of technology and biotechnology. These developments highlight AI's transformative potential in medicine, from expediting drug discovery to personalizing treatments. If AI can design drugs, could it also predict the unintended consequences of its creations? This post was generated by my custom-built personal agent, powered by LLMs and designed to operate my computer. If you're curious about how it works, feel free to ask!

US-based Triomics snaps $15M to automate oncology workflows with Generative AI Triomics, a San Francisco-based healthcare startup, has raised $15 million to streamline workflows for cancer centres using generative artificial intelligence (GenAI). Their technology focuses on automating tasks currently handled manually, aiming to improve efficiency and patient care. The funding was led by leading Silicon Valley investors, including Y Combinator, Lightspeed, General Catalyst, and Nexus Venture Partners. Notably, whenever possible, Triomics seeks to pass costs directly to pharmaceutical sponsors, minimising the financial burden on healthcare providers. Additionally, performance-based agreements ensure partners see a return on investment before incurring any out-of-pocket expenses. In the relative note, we also reported yesterday about a female-led Opmed.ai that secured $15M to address healthcare labour shortages with AI. What problem is the startup solving Co-founded by Sarim Khan (CEO) and Hrituraj Singh (CTO), Triomics focuses on a critical challenge in healthcare, particularly within oncology: the vast amount of unstructured data locked away in free-text patient records. Traditionally, accessing this data relies on manual chart review, a laborious pro…

With 3 days to go to the largest gathering of investors, innovators, and entrepreneurs in Southern California, our next session at TechCon SoCal will focus on "The Next Generation of Medicines." Hans Keirstead, Chairman and CEO of AIVITA Biomedical, Inc. Biomedical, will lead this discussion. Renowned for his pioneering work in stem cell research and regenerative medicine, Hans will provide an in-depth look into the future of medical treatments and innovations. In the current landscape, the field of medicine is undergoing rapid advancements driven by cutting-edge research and technology. Hans Keirstead will discuss the latest breakthroughs in personalized medicine, immunotherapy, and biotechnology. These innovations promise to revolutionize patient care, offering more effective and targeted treatments for various diseases. The session will highlight how these emerging therapies are poised to improve health outcomes and extend lives, reflecting a significant shift in how we approach medical treatment today. Reflecting on the past, the journey to today's medical innovations has been marked by significant milestones and relentless research. Hans Keirstead's work, particularly in stem cell research, has paved the way for many of the advancements we see now. Early breakthroughs in regenerative medicine and the development of novel therapies have laid the foundation for current and future innovations. This session will revisit these key historical developments, providing context to the evolution of medical science and setting the stage for what lies ahead in the next generation of medicines. OPEN Silicon Valley TIE San Diego Interlock Capital Orange County OC Startup Council The Brink SBDC EvoNexus UC San Diego SDSU College of Sciences Pismo Ventures Cross Ocean Ventures Startup Steroid - Deal Flow | SPVs | Demo Day Platform Alliance for Southern California Innovation Spark Growth Ventures SoCal Startup Day Reflect Ventures Wharton Alumni Angels NuFund Venture Group Flok Labx Ventures Mercury Pankaj Kedia Serhat Pala Neal Bloom David Saxton Cheryl K Goodman Ellen M. Chang Niraj Desai Akash Pai Sufyan Subzwari Jonah Peake 🐺 Ella Napata Stephen Silver Fred Grier Scott Fox 🦊 Atlás Blake Eric Eide #TechconSoCal2024 #IndustryExperts #TechConference #InnovationSummit #TechTalks #startupsteroid #innovations #technologynews #networking #artificialintelligence #digitalhealth #robotics #startups #AngelInvestors #vc #SandDiegoStartup #founders #consumertech

LAST 3 DAYS to apply for the Merck Digital Sciences Studio #accelerator program that offers: ✔️ Up to $150,000 investment via a SAFE; ✔️ $150,000 in Azure compute credits; ✔️ Access to Microsoft's Founders Hub resources; ✔️ 10-month hands-on #accelerator program providing #mentorship, #coaching, training, support, #community, and #investment to enable the next generation of innovative technologies from USA ✔️ Opportunities to #showcase your #technologies in #collaboration with discovery and clinical scientists at Merck. ✔️ Technology support is provided by Microsoft for Startups.